Free Trial

bioAffinity Technologies Q1 2023 Earnings Report

bioAffinity Technologies logo
$0.83 +0.02 (+2.47%)
As of 02/21/2025 03:49 PM Eastern

bioAffinity Technologies EPS Results

Actual EPS
-$0.18
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

bioAffinity Technologies Earnings Headlines

Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
bioAffinity Technologies Reports Strong Q3 Growth
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat